April 27, 2009 - Varian Medical Systems is showcasing the its full spectrum of prostate cancer treatment technologies, including brachytherapy, IMRT and SBRT, at the American Urological Association (AUA) Meeting at McCormick Place in Chicago from April 25-30.

"At the AUA meeting, we'll be exhibiting our latest solutions for high-dose-rate brachytherapy, planning for low-dose brachytherapy with permanent seed implants, 3D conformal radiotherapy, intensity-modulated radiotherapy (IMRT), and stereotactic body radiotherapy (SBRT)," said Calvin Huntzinger, MS, senior director, Varian Surgical Sciences. Each is a different approach to targeting prostate tumors with radiation.

Varian recently produced a clinical perspectives paper entitled “Early-stage prostate cancer treatment alternatives,” highlighting research that contrasts these and other approaches to prostate cancer treatment.

Varian will be showcasing the following radiotherapy solutions at the AUA meeting:

- The VariSource and GammaMed lines of HDR brachytherapy afterloaders, a computer-controlled device for guiding a needle or catheter as it places a radiation source directly into a tumor and holds it there for a prescribed period of time while the dose is delivered.
- VariSeed brachytherapy treatment planning software, which facilitates the permanent implantation of tiny radioactive seeds, each the size of a grain of rice, directly into the prostate.

Also showcased will be the Novalis Tx platform for image-guided radiotherapy and radiosurgery, a suite of tools made by Varian and BrainLAB for delivering external beam radiotherapies, including 3D conformal, IMRT, RapidArc radiotherapy and SBRT.

Novalis Tx can also deliver RapidArc radiotherapy, making it possible to complete an IMRT or SBRT treatment very quickly by dosing the entire tumor volume with a single rotation of the treatment machine around the patient.

The American Urological Association Meeting will take place at McCormick Place in Chicago, April 25-30.

For more information: www.varian.com


Related Content

News | Women's Health

Nov. 3, 2025 — —A new radioimmunotherapy approach has the potential to cure human epidermal growth factor receptor 2 ...

Time November 04, 2025
arrow
Feature | Kyle Hardner

Radiotherapy contributes to about 40% of all cancer cures but still lags behind systemic therapy in funding and ...

Time October 21, 2025
arrow
News | Radiation Oncology

Sept. 02, 2025 — Alpha Tau Medical Ltd., the developer of the alpha-radiation cancer therapy Alpha DaRT has announced ...

Time September 05, 2025
arrow
News | Radiation Oncology

May 2, 2025 — GE HealthCare has announced an intended expansion of its radiation oncology portfolio as well as the ...

Time May 03, 2025
arrow
News | Radiology Education

April 21, 2025 — On June 20, the American Society of Radiologic Technologists (ASRT) will award Life Member status to ...

Time April 21, 2025
arrow
News | Radiology Business

April 16, 2025 — According to a new report, the U.S. Radiotherapy Market is projected to reach $2.49 billion by 2030 ...

Time April 17, 2025
arrow
News | ASTRO

March 14, 2025 — Another pivotal milestone in the nation’s fight against cancer recently took place with the ...

Time March 17, 2025
arrow
News | Computed Tomography (CT)

Royal Philips recently received 510(k) clearance from the US Food and Drug Administration (FDA) for its detector-based ...

Time November 13, 2024
arrow
News

Aug. 5, 2024 — Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that adding ...

Time August 09, 2024
arrow
News | PET-CT

July 31, 2024 — In a head-to-head comparison with FDG PET/CT, FDG PET/MRI demonstrated comparable or superior diagnostic ...

Time July 31, 2024
arrow
Subscribe Now